LY4268989 (MORF-057) is an experimental oral tablet that contains a compound called LY4268989 adipic acid. In this study, the medicine is being tested to see if it can help adults with moderately to severely active ulcerative colitis reach clinical remission. Researchers hope that the drug will reduce the inflammation in the colon, lessen symptoms such as bleeding and diarrhea, and improve patients’ overall health. The trial will first evaluate how well the medicine works after 10 weeks of treatment and then continue to check its safety and effectiveness over a longer period of up to one year for those who respond early.

Ulcerative colitis, active moderate – It is a chronic inflammation of the colon that causes ongoing diarrhea, blood in the stool, and abdominal cramping. In moderate activity, symptoms are noticeable but not disabling. The inflammation may spread gradually, causing the lining to become thicker and ulcerated. Flare‑ups can occur, followed by periods of less severe symptoms. Repeated inflammation can lead to changes in the colon lining.
Ulcerative colitis, active severe – This form leads to intense diarrhea, frequent blood, urgent need to go, and significant abdominal pain. Inflammation involves larger areas of the colon and causes deeper ulceration. Symptoms are often continuous with few breaks. The disease can cause swelling and loss of tissue in the colon lining. The inflammation may persist and worsen over time.
Ulcerative colitis (UC) – Ulcerative colitis is a long‑lasting disease that inflames the inner lining of the large intestine. It typically starts in the rectum and can extend upward through the colon. The condition causes recurring episodes of bowel urgency, blood, and abdominal discomfort. Inflammation may wax and wane, with periods of flare and remission. Over time, the colon lining may become thinner and develop small sores.